Literature DB >> 1979168

Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential.

H K Shu1, R J Pelley, H J Kung.   

Abstract

Avian c-erbB is activated to a leukemia oncogene following truncation of its amino-terminal, ligand-binding domain by retroviral insertion. The insertionally activated transcripts encode protein products that have constitutive tyrosine kinase activity and that can induce erythro-leukemia but not sarcomas. We have found that a single point mutation within the ATP-binding pocket of the tyrosine kinase domain in this truncated molecule can increase the ability of this oncogene to induce anchorage-independent growth of fibroblasts in vitro and fibrosarcoma formation in vivo. Associated with this increased transforming potential is a corresponding increase in the kinase activity of the mutant erbB protein product. The mutation, which converts a valine to isoleucine at position 157 of the insertionally activated c-erbB product, is at a residue that is highly conserved within the protein kinase family. To our knowledge, this is the first demonstration of a point mutation in the ATP-binding pocket that activates a tyrosine kinase.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979168      PMCID: PMC55112          DOI: 10.1073/pnas.87.23.9103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Regulation of the epidermal growth factor receptor by phosphorylation.

Authors:  P J Bertics; W Weber; C Cochet; G N Gill
Journal:  J Cell Biochem       Date:  1985       Impact factor: 4.429

2.  The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA.

Authors:  J W Taylor; J Ott; F Eckstein
Journal:  Nucleic Acids Res       Date:  1985-12-20       Impact factor: 16.971

3.  A mutation at the ATP-binding site of pp60v-src abolishes kinase activity, transformation, and tumorigenicity.

Authors:  M A Snyder; J M Bishop; J P McGrath; A D Levinson
Journal:  Mol Cell Biol       Date:  1985-07       Impact factor: 4.272

4.  Protein phosphorylation at tyrosine is induced by the v-erbB gene product in vivo and in vitro.

Authors:  T Gilmore; J E DeClue; G S Martin
Journal:  Cell       Date:  1985-03       Impact factor: 41.582

5.  Induction of angiosarcoma by a c-erbB transducing virus.

Authors:  S E Tracy; B A Woda; H L Robinson
Journal:  J Virol       Date:  1985-05       Impact factor: 5.103

6.  Antibodies against a synthetic peptide as a probe for the kinase activity of the avian EGF receptor and v-erbB protein.

Authors:  R M Kris; I Lax; W Gullick; M D Waterfield; A Ullrich; M Fridkin; J Schlessinger
Journal:  Cell       Date:  1985-03       Impact factor: 41.582

7.  c-erbB activation in avian leukosis virus-induced erythroblastosis: clustered integration sites and the arrangement of provirus in the c-erbB alleles.

Authors:  M A Raines; W G Lewis; L B Crittenden; H J Kung
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

8.  c-erbB activation in ALV-induced erythroblastosis: novel RNA processing and promoter insertion result in expression of an amino-truncated EGF receptor.

Authors:  T W Nilsen; P A Maroney; R G Goodwin; F M Rottman; L B Crittenden; M A Raines; H J Kung
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

9.  Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences.

Authors:  J Downward; Y Yarden; E Mayes; G Scrace; N Totty; P Stockwell; A Ullrich; J Schlessinger; M D Waterfield
Journal:  Nature       Date:  1984 Feb 9-15       Impact factor: 49.962

10.  Mutations in the cytoplasmic domain of EGF receptor affect EGF binding and receptor internalization.

Authors:  R Prywes; E Livneh; A Ullrich; J Schlessinger
Journal:  EMBO J       Date:  1986-09       Impact factor: 11.598

View more
  18 in total

1.  Dissecting the activating mutations in v-erbB of avian erythroblastosis virus strain R.

Authors:  H K Shu; R J Pelley; H J Kung
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

2.  The amino-terminal 14 amino acids of v-src can functionally replace the extracellular and transmembrane domains of v-erbB.

Authors:  M McMahon; R C Schatzman; J M Bishop
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

3.  Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain.

Authors:  M K Webster; D J Donoghue
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

4.  The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection.

Authors:  J E Strong; P W Lee
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

5.  Modulation of erbB kinase activity and oncogenic potential by single point mutations in the glycine loop of the catalytic domain.

Authors:  H K Shu; C M Chang; L Ravi; L Ling; C M Castellano; E Walter; R J Pelley; H J Kung
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

6.  Induction of renal adenocarcinoma by a nonmutated erbB oncogene.

Authors:  C A Taglienti-Sian; B Banner; R J Davis; H L Robinson
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

7.  Characterization of an activated mutant of focal adhesion kinase: 'SuperFAK'.

Authors:  Veronica Gabarra-Niecko; Patricia J Keely; Michael D Schaller
Journal:  Biochem J       Date:  2002-08-01       Impact factor: 3.857

Review 8.  Tyrosine kinase inhibitors in preclinical development.

Authors:  M L Levitt; P P Koty
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

9.  Transforming properties and substrate specificities of the protein tyrosine kinase oncogenes ros and src and their recombinants.

Authors:  S M Jong; C S Zong; T Dorai; L H Wang
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

Review 10.  Growth factors and tyrosine protein kinases in normal and malignant melanocytes.

Authors:  R Halaban
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.